Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03970759 · ClinicalTrials.gov registry record
Meta-analysis of Stannous Fluoride and the Effects on Gingival Health
A clinical trial, sponsored by Procter and Gamble.
- Completed
- Registry status
- 2,890
- Enrollment target
NCT03970759: Completed study, sponsored by Procter and Gamble.
NCT03970759 is a clinical trial that has completed, run by Procter and Gamble. The registered enrollment target is 2,890 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03970759 has completed, sponsored by Procter and Gamble.
- COMPLETED
- Registry status
- 2,890 participants
- Enrollment target
Study Summary
The aim of this 18 study analysis was to compare the effect of bioavailable stannous fluoride (SnF2) dentifrices when used up to 3 months on gingivitis relative to a positive or negative control dentifrice.
Primary Outcome
Change from baseline as measured on number of bleeding sites (gingival bleeding index or Loe Silness index).
Interventions
- DRUG Stannous Fluoride Dentifrice
- DRUG Positive control dentifrice
- DRUG Negative control dentifrice
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,890 participants |
| Start Date | 2018-01-08 |
| Est. Completion | 2018-11-30 |
What the finished NCT03970759 record still lists
NCT03970759 is an observational study that tracks outcomes without assigning an intervention. Its 2,890 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 3 interventions - of which Stannous Fluoride Dentifrice is the first listed.
NCT03970759 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03970759 about?
NCT03970759 is a clinical study titled "Meta-analysis of Stannous Fluoride and the Effects on Gingival Health". The aim of this 18 study analysis was to compare the effect of bioavailable stannous fluoride (SnF2) dentifrices when used up to 3 months on gingivitis relative to a positive or negative control dentifrice.
What is the current status of trial NCT03970759?
This trial is currently completed. The enrollment target is 2,890 participants. The study started on 2018-01-08. Estimated completion is 2018-11-30.
What interventions are being tested in trial NCT03970759?
The interventions under investigation include: Stannous Fluoride Dentifrice (DRUG), Positive control dentifrice (DRUG), Negative control dentifrice (DRUG).
Who is sponsoring clinical trial NCT03970759?
This trial is sponsored by Procter and Gamble, which has 70 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06273436 · 2,894 participants · NA
Healing, Equity, Advocacy and Respect for Mamas
- NCT05564377 · 2,900 participants · Phase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- NCT07222995 · 2,900 participants · NA
Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs
- NCT05624450 · 2,870 participants · Phase 3
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI